News & Events about Castle Biosciences Inc.
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has teamed up with IMPACT Melanoma, one of the nation's leading non-profit organizations dedicated to melanoma prevention and early detection, as sunscreen...
Castle Biosciences, Inc. (NASDAQ:CSTL Get Rating) insider Derek J. Maetzold sold 969 shares of the businesss stock in a transaction dated Wednesday, April 12th. The shares were sold at an average price of $22.61, for a total value of $21,909.09. Following the sale, the insider now ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the 22nd Annual...
Castle Biosciences, Inc. (NASDAQ:CSTL Get Rating) Director Daniel Bradbury sold 10,300 shares of the companys stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $22.14, for a total value of $228,042.00. Following the sale, the director now directly ...
Business Wire
2 months ago
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today shared new performance data from a novel, multi-center, independent cohort demonstrating how the independent risk-stratification of DecisionDx-SCC (the Companys 40-gene...